**Table of Contents**

Letter from Leadership .............................................. 1  
International Research Review ................................. 2  
JDRF Canadian Clinical Trial Network ....................... 8  
Our Partners .......................................................... 11  
Our Successes ........................................................ 13  
Continued Support .................................................. 21  
Major and Corporate Donors ...................................... 23  
Canadian Research Funded in 2012 ............................ 26  
Financial Review .................................................... 30  
Board of Directors, Chapter Locations ....................... 31

---

**JDRF: Connected to You, Connected to a Cure**

As the leading global organization focused on type 1 diabetes (T1D) research, JDRF has remained ever committed to helping people at all ages and all stages of the disease live better, longer, healthier lives while we work toward a cure. They are the reason JDRF exists and remain at the forefront of everything we do.

In its 38th year, JDRF Canada is proud to be connected to the T1D community across the country and around the globe. From researchers, to families, volunteers, and partners; to those living with T1D every day, we are all connected, sharing a common goal of finding a cure for this disease and its complications.

As valuable members of the T1D community, you are truly ambassadors for this disease.

Connected together, there is no telling what can be accomplished.

---

**Eileen Sallis – B.C. & Yukon Region**

“My twin grandchildren, Ethan and Emily, have T1D. First Ethan, then six months later Emily. I admire my son and daughter-in-law, John and Michelle, from the bottom of my heart for their dedication. Michelle is an angel. After their diagnosis, I thrust myself into organizing a Women’s Charity Golf Tournament at the Kelowna Golf & Country Club raising awareness and funds for JDRF. How could you not support an organization that puts money directly into research? It seems they are getting closer and closer to a cure, and that is my commitment to JDRF.”
Letter From Leadership

Since JDRF Canada’s establishment in 1974, we continue to experience tremendous success as an organization leading the fight against type 1 diabetes (T1D), and we are very proud of our accomplishments. JDRF witnessed exceptional results in 2012, and as we move into 2013 we will build on this momentum to continue to grow our programs and research mission.

As the leading funder and advocate for T1D research, JDRF continues with our commitment to improve the lives of all people affected by T1D by accelerating progress on the most promising research opportunities to cure, better treat and prevent this disease. JDRF continues to be driven by passionate, grassroots volunteers, connected to all ages and all stages of T1D and their support remains at the forefront of everything we do. We are all connected in this journey to cure T1D and its complications, and with the dedication and support of people like you, we can continue to reach critical research milestones in our efforts to conquer T1D.

Since the 2009 partnership with the Federal Government, JDRF Canadian Clinical Trial Network (JDRF CCTN) continues to be at the forefront of Canadian and worldwide efforts to find a cure for T1D. As JDRF CCTN remains one of the largest government partnerships in Canadian diabetes history, it has rapidly evolved into a groundbreaking initiative that continues to accelerate solutions, for the management, care and cure of T1D. JDRF CCTN was successfully delivered in full on March 21, 2012 and has not only met, but far exceeded the deliverables outlined in the partnership with the Federal Government. JDRF CCTN launched not three, but nine clinical trials in this first phase, as well as two Research and Development (R&D) projects. Five of the clinical trials and one of the R&D projects are Artificial Pancreas-related. JDRF CCTN continues to aggressively translate T1D science into treatments, drugs and therapies to help people with T1D live healthier lives now, while we continue to work toward a cure.

T1D connects communities both in Canada and around the world. As such, JDRF’s influence and leadership extends beyond funding research as we partner with industry, governments, foundations, academia and clinicians to ensure that JDRF and its partners are aligned and working toward a common goal of curing, better treating and preventing T1D. These connections across Canada are building blocks to achieve a common goal of curing T1D, and are only possible with the efforts of our dedicated volunteers and staff who truly believe in the cause. In the coming years, JDRF is committed to expanding JDRF CCTN and extending its trials to individuals who are facing T1D across Canada. This will be done while we continue to fund groundbreaking research across the country and develop new strategies to accelerate the translation of scientific breakthroughs into potential clinical trials.

Of course, all of this research toward a cure takes resources. We had another successful year in that respect, concluding fiscal year 2012 with $30 million in total revenue, including JDRF CCTN. Our core programs and fundraising initiatives raised over $24 million which was only possible with your continued support. In 2012, the TELUS Walk to Cure Diabetes raised over $7.7 million and the JDRF Ride for Diabetes Research raised over $7.5 million. The growth of other fundraising efforts also continued to climb, with our Galas raising over $2.9 million, and Major Gifts generating over $2.9 million.

The success of these programs and our achievements could not have been accomplished without you. For that, we extend our sincere appreciation.

We are all connected in this search for a cure, and our continued success is only possible through the incredible support of donors, partners, supporters, staff, and volunteers who truly understand the importance of JDRF’s work.

We are very proud of the results JDRF has achieved as an organization, and as we remain connected we are able to thrive because of our exceptional partnerships and dedication across Canada. Your commitment, partnership, and continued support will help us continue to achieve remarkable things. We are all connected, and together we will continue to work toward a cure.

Aubrey Baillie
Chairman of the Board of Directors,
JDRF

Andrew McKee
President and CEO,
JDRF
Janelle Tyler & Erica Griffiths – Atlantic Region

“After our sons, Kyle and Davis, were diagnosed, we saw an opportunity to raise funds and awareness within the schools. We accomplish this through our partnership in organizing Walks and events like Spin and Swish, and Touch-a-Truck. We stay connected and motivated because of the strong friendships and community support. Its not just about raising money, JDRF cares about their families and they want to find a cure.”

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research and the largest charitable funder and advocate for T1D research. Our mission is to find a cure for diabetes and its complications through the support of research.

Driven by passionate, grassroots volunteers, JDRF is committed to improving the lives of people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing the disease. JDRF continuously strives to help people at all ages and all stages of T1D live better, longer, healthier lives.

Since its founding in 1974, JDRF has awarded more than $1.7 billion (US) globally to T1D research. JDRF research efforts have helped to significantly improve the care of people living with this disease and have expanded the critical scientific understanding of T1D. JDRF efficiently and effectively directs resources to research designed at finding a cure and developing new treatments, drugs and therapies with more than 80 per cent of JDRF’s expenditures directly supporting research, research-related education, and advocacy.

Through local chapters, international affiliates, volunteers, staff and corporate partnerships in over 100 locations worldwide, JDRF offers a diverse support network, outreach programs, advocacy initiatives, and innovative fundraising programs.

For more information, or to make a donation, please visit jdrf.ca.
International Research Review

We’re not imagining progress, we’re making it happen

JDRF’s investments in research have positively impacted the type 1 diabetes (T1D) research knowledge base including the artificial pancreas systems, beta cell encapsulation and regeneration, treatments for diabetic eye disease, improved insulins and insulin delivery, and secondary prevention strategies to delay insulin dependence.

“Diabetes research is accelerating at great speeds. Our responsibility as researchers to the T1D community around the world is to ensure we continue to pursue the best avenues to ultimately find a cure.” - Tim Kieffer, Ph.D., Professor, Laboratory of Molecular & Cellular Medicine, Department of Cellular & Physiological Sciences, Department of Surgery, Life Sciences Institute, The University of British Columbia

JDRF focuses on delivering a sustained stream of new, life-changing therapies from the near-term to the long-term. We drive research across the entire scientific spectrum, from discovery in the laboratory to delivery of new technology and treatments for patients.

JDRF’s unique role as the global catalyst and integrator of T1D research is critical, serving a vital role in promoting and creating collaborations for research and development and promoting the integration of different technologies to deliver on the JDRF mission.

Our beta cell growth research is stimulating

Using drugs to stimulate beta cell proliferation - in which beta cells multiply to form new, functional beta cells - is getting closer to reality. JDRF-supported researchers identified new pathways that control beta cell proliferation and might be activated with drug therapies.

A top priority for JDRF regeneration research is to discover physiologic mechanisms and pathways that promote beta cell regeneration, proliferation, and survival. Understanding how the body normally regulates expansion of beta cell mass could point the way to new targets for development of drugs that can stimulate this process in people with T1D.

JDRF-supported researchers have made significant progress toward a more complete picture of how beta cell expansion is controlled. The researchers identified four different pathways that contribute to beta cell proliferation. Some of these pathways have been activated with prototype drugs in animal studies; others are still at an early stage of research.

Paula Moorhouse – North Eastern Ontario Region

“Our family and friends have rallied around JDRF’s TELUS Walk to Cure Diabetes since 2005 when Jason was diagnosed. Our family organizes three big fundraisers gearing up for the Walk each year – a lottery, a Super Breakfast event, and a cinnamon bun fundraiser. Since 2005 we have raised over $65,000. We fundraise for our son. Finding a cure is our goal for Jason, and we expect he will see one in his lifetime, and we believe JDRF will be leading that.”
Hope for future progress
Although more research is needed to validate these pathways and identify safe, suitable targets for drug development, JDRF remains committed to pursuing promising leads for better understanding beta cell regeneration. Using that knowledge, new stimulates regeneration has the potential to restore beta cell function in large numbers of people with T1D, using drug-based approaches.

We’re locking out the autoimmune attack
JDRF-funded scientists are designing unique technologies to protect implanted beta cells from damage, with the goal of restoring insulin independence.

JDRF-supported researchers are investigating new approaches to producing insulin by implanting insulin-producing beta cells or their precursors into the body. The challenge is that beta cells implanted into people with T1D are attacked by the immune system.

To protect beta cells from autoimmune attack, researchers are working to build a bioengineered “shield” around them—an approach referred to as encapsulation. The goal is for these encapsulated beta cells to sense a person’s blood-sugar levels, produce insulin as needed, and persist in the long term.

In FY2012, JDRF significantly expanded funding opportunities for encapsulation research.

We’re on the path to even more advances
JDRF-funded researchers have discovered a glucagon formulation that remains stable in liquid form, bringing us one giant step closer to multi-hormone treatment technologies.

Glucagon is a naturally occurring hormone that responds to decreasing blood glucose by releasing additional glucose into the bloodstream. When partnered with insulin—which delivers glucose from the bloodstream to the cells—it helps maintain optimal blood-glucose balance. However, commercially available glucagon does not remain stable in a liquid form for long after the powder and solution are combined, so it must be taken immediately and any unused portion must be discarded.

Envisioning a multi-hormone artificial pancreas system
JDRF-supported researchers found that by increasing the pH of the glucagon solution, they could create a glucagon formulation that remains stable and nontoxic to cultured cells for at least seven days. The researchers think that this formulation could be usable in standard diabetes pumps, broadening the use of glucagon to help prevent hypoglycemia in people with T1D and opening a path to future-generation artificial pancreas systems that dispense more than just insulin.

We’re making insulin smarter
Imagine taking insulin once a day or less, with a substantially reduced

“As a founding family of JDRF, we have seen great progress in research that has given us improved diabetes management tools, and continues to take us steps closer to a cure.” Lorne Shiff, JDRF Canada Board Member

Louis-Philippe Thibodeau – Quebec Region
“I am lucky to have a healthy family. So many people are not as fortunate. That’s why I connected with JDRF by becoming a volunteer. I am thankful for the valuable contributions of my colleagues at the Caisse de dépôt et placement du Québec and the support of my family.”
(once or twice) need for checking blood glucose. JDRF is working on glucose responsive insulin, a treatment that would work exactly when and how the body needs it.

For people living with T1D, current insulin treatment demands constant monitoring and arduous administration. Glucose responsive insulin (GRI) has the potential to improve glucose control, decrease or eliminate the need to test or monitor blood-glucose levels, improve quality of life through the reduced burden of T1D management, and reduce the risk of diabetes complications.

Developing a safe and effective GRI product will not be easy. It will require out-of-the-box approaches and a long-term vision and leadership from JDRF.

**Challenging the world to invent GRI**

To encourage new thinking in GRI research, JDRF offered a $100,000 Challenge Prize for those few select visionaries across the globe who could propose a creative solution to achieve a GRI product. JDRF launched this challenge in partnership with InnoCentive, a pioneer in open innovation and crowdsourcing.

From a pool of 63 applications, 23 proposals were selected for final review by a panel of external experts. Ultimately, three ideas were selected to receive the Agnes Varis GRI Grand Challenge Prize, a project made possible with support from The Agnes Varis Charitable Trust.

None of the winning applicants had previous experience in T1D research, demonstrating that the Challenge Prize had succeeded in engaging a diverse group of researchers and stimulating fresh ideas from the scientific community.

**Next steps for progress in GRI research**

To continue down this innovative path in GRI research, JDRF is now embarking on the next phase—i.e., “reduction to practice”—of these theoretical ideas. This phase will support early discovery research to evaluate and develop the theoretical proposals of the prize winners. JDRF will also seek to support additional research ideas from select prize applicants who did not win but who had novel and potentially feasible ideas.

**Blood proteins associated with diabetic kidney disease**

Researchers studied 628 individuals with T1D and normal kidney function to search for biomarkers of kidney disease risk in people with T1D.

The risk of diabetic kidney disease is very difficult to predict in people with T1D, since only some people with T1D develop this complication. Researchers have been looking for biomarkers that can identify individuals at high risk for kidney disease, in order to facilitate earlier treatment and better management of this serious T1D complication. This year, JDRF-supported researchers took a major step toward that goal.

High levels of two proteins in the blood, TNF receptors 1 and 2 (TNFR1 and TNFR2), were discovered to be strongly associated with susceptibility to progression to diabetic kidney disease.

**Potential for new diagnostic tests**

Although scientists do not yet understand how TNFR1 and TNFR2 are involved in the development of kidney disease, the findings suggest that these two proteins may have value as predictors of this complication in both T1D and type 2 diabetes. This research could be used to help develop a simple blood test to predict the development or progression of kidney disease in people with diabetes.

Diagnostic tests such as potential blood tests based on TNFR1 and TNFR2 would help target existing treatments to people who are most at risk and also help researchers select the most appropriate people to recruit for clinical trials to test new therapies for diabetic kidney disease.

**Our researchers know that T1D is a balancing act**

A JDRF-supported clinical trial is enrolling individuals with newly diagnosed T1D to test a novel therapy
for slowing down damage to insulin-producing cells in the pancreas.

JDRF-funded researchers in the United Kingdom are investigating the use of proinsulin peptide, a precursor of the hormone insulin. The study seeks to prevent or slow down the destruction of the insulin-producing cells in the pancreas. This destruction is a hallmark of T1D and leads to insulin dependence.

In its initial phase, this study will address the safety and optimal dosing regimen of proinsulin peptide therapy. If successful, these studies could advance treatments to reduce or possibly remove the need for insulin injections.

**We want to protect future generations from T1D**

CONCEPTT is the first international clinical trial designed to determine whether use of continuous glucose monitoring can improve glucose control in women with T1D who are pregnant or planning pregnancy.

For a pregnant woman with T1D, maintaining tight blood-glucose control is critical, for both her own health and that of her baby. Women with T1D have a higher risk of preeclampsia, or dangerously high blood pressure during pregnancy, as well as increased labor and delivery complications. Babies born to women with T1D are at increased risk of high birth weight, premature birth, and other potentially serious birth complications.

Research has shown that good glucose control during pregnancy can reduce the excess risks that are due to diabetes and improve outcomes for both mother and child. But it is not always an easy task to achieve optimal control during pregnancy.

**An international trial of CGM in pregnancy**

The CONCEPTT study is the first multi-centre, international clinical trial testing the use of continuous glucose monitoring (CGM) during pregnancy. Researchers are enrolling more than 100 women with T1D who are planning to become pregnant and more than 200 women with T1D who are in the first few months of pregnancy.

Women who participate in the trial are randomly assigned to receive standard intensive insulin therapy either with or without real-time CGM. The trial will evaluate whether CGM use improves glucose control and reduces pregnancy complications for mother and child.

**Improving pregnancy outcomes for women with T1D**

CONCEPTT exemplifies JDRF’s commitment to helping people with T1D at all ages and all stages of the disease, including finding ways to promote healthy pregnancies for women with T1D. If successful, this trial has the potential to quickly change the medical standard of care for pregnant women with T1D around the world.

**We put our research to the test**

JDRF-funded researchers developed a blood test to detect beta cell death that may diagnose the risk of developing T1D and may prove useful to evaluate the effectiveness of potential therapies.

Current tests to predict the development of T1D do not directly measure beta cell death. Indeed, the destruction of beta cells that begins well before the onset of T1D...
is normally not detected until a significant number of beta cells have been lost and a person’s glucose control is affected. JDRF-funded researchers have discovered that dying beta cells release DNA with unique modifications into the bloodstream. The research team then developed a simple blood test to measure the modified beta cell DNA. Using this blood test, the researchers were able to detect beta cell death prior to the onset of T1D in mice. In preliminary results, the Yale researchers found that the blood test could be useful for detecting beta cell death in individuals with new-onset T1D.

We want to stop T1D before it starts
We all imagine a day when a vaccine is made that will eliminate the occurrence of T1D. Thanks to a collaboration between JDRF and Selecta Biosciences and other academic research partners, that vision may one day become a reality. Antigen-specific tolerogenic vaccines are designed to stop the specific autoimmune response that causes TID without damaging the immune cells that protect against infection by bacteria, viruses, and other pathogens. A targeted vaccine could stop the autoimmune process before a person becomes insulin dependent.

T1D vaccines could have other, wide-ranging benefits. Such vaccines could be used with other therapies to preserve remaining beta cell function in individuals recently diagnosed with T1D or to protect newly regenerated or transplanted insulin-producing beta cells in people with established T1D.

Partnerships for vaccine development
JDRF is supporting Selecta Biosciences’ development of a unique nanoparticle-based vaccine technology that may help to better treat and potentially prevent TID. Through this research partnership, JDRF will provide performance-based milestone financial support and expertise, with the goal of applying Selecta’s vaccine technology toward the development of vaccines for T1D.

JDRF also supports a variety of academic investigators who are working on ways to make a vaccine possible through nanoparticle research. Nanoparticles—very small packages used as a way to deliver components that trigger the immune system—appear to have the ability to effectively mimic the natural immune system tolerance processes. Such nanoparticles allow the delivery of multiple important triggers of immune tolerance, should minimize side effects by being more specific to T1D, and allow better control of the production of the particles to specifically modify the immune response. While this research has so far been conducted only in mice, if successfully applied to humans, it could provide a potential pathway to controlling the autoimmunity that underlies T1D.

JDRF believes that vaccine research is one of the most promising approaches to prevent or halt beta cell–specific autoimmunity in T1D. This is an extremely challenging area of research. However, we continue to support new technology advances that may increase the chances of successfully developing next-generation vaccine technology for the prevention of T1D.

“Being diagnosed with T1D has not held me back from achieving my dreams, but a cure would mean the world to me. I have great faith that with continued support, JDRF research will find a cure for diabetes and end the daily challenges of a life with T1D.”

Michael Thornton, JDRF Advocate and Youth Ambassador.
“JDRF is one of our charities of choice through the Parkwood Building a Difference Foundation. We have pledged to donate $125,000 to JDRF through various fundraising initiatives like the Parkwood Benefit House, a yearly golf tournament and the TELUS Walk to Cure Diabetes. The determination of the children and families living with diabetes inspires us as a company to go out and raise more money.”
JDRF’s diabetes research pipeline continues to be in every sense, groundbreaking and innovative. As you know, 2011 marked an especially significant year for JDRF and the type 1 diabetes (T1D) research community in Canada with the launch of nine clinical trials. Now in the third year of our partnership with the Government of Canada, JDRF Canadian Clinical Trial Network (JDRF CCTN) continues to conduct advanced clinical trials of revolutionary treatments and technologies for T1D providing Canadians access to the latest diabetes breakthroughs. Supported through a $20 million commitment from the Federal Government and an additional $13.9 million commitment from JDRF, this $33.9 million investment is helping to ensure that Canada maintains its practice of innovation in diabetes research, and works with us to get one step closer to our ultimate goal.

In three short years, JDRF CCTN has rapidly flourished into a groundbreaking initiative that is speeding up the pace for solutions to cure, better treat, and prevent T1D. The largest government partnership in JDRF Canada history, JDRF CCTN is at the centre of Canadian and worldwide efforts to find a cure, with a broad mission spanning advanced technology like the artificial pancreas, cutting-edge immune therapies, and other genetic interventions. This ambitious initiative is bringing new, advanced therapies for diabetes and its complications to Canadians faster and increasing our national capability for clinical trials.

There has been a fundamental change in the way clinical research in diabetes is done in Canada; JDRF CCTN has a strong focus on a mix of industry partnership, academic collaboration, government and non-profit cooperation. Since JDRF CCTN was announced in 2009, the network continues to work with a strongly established team, including: highly experienced doctors, scientists, and other clinical support professionals who are overseeing clinical trial operations; as well as doctors and nurses from leading institutions across southern Ontario, including The University Health Network, The Hospital for Sick Children, Mount Sinai Hospital, Sunnybrook Hospital, the Children’s Hospital of Eastern Ontario, McMaster Children’s Hospital, Western University, St. Joseph’s Health Care London, and London Health Sciences Centre.

JDRF CCTN aggressively translates discoveries into treatments, drugs, and therapies that will help people with T1D live healthier lives now, while we work toward a cure. Hard work, dedication, determination, and commitment have been invested in high-profile, practice-changing clinical trials in partnership with leading researchers and medical centres throughout southern Ontario. With the first study participant enrolled on March 28, 2011, JDRF CCTN has successfully launched nine clinical trials and two technology projects, including five Artificial Pancreas-related trials, far exceeding our initial goal of three. JDRF CCTN is a shining example of how your support is getting us closer to a cure.

Through the course of 2013, we will continue enrolling patients and providing information about the trials as they open to the public. JDRF CCTN has the ability to perform trials in all our therapeutic areas—from testing innovations related to the Artificial Pancreas Project, to new immune-based therapies, to the management and treatment of diabetes complications.

In the coming year, JDRF is committed to building JDRF CCTN and extending its trials to individuals and families in every corner of Canada facing T1D. JDRF has one goal in mind for the network—expanding a coast-to-coast research network—a network that will change the Canadian landscape forever, pushing forward to our ultimate goal of finding a cure for T1D. For more information, please visit jdrf.ca/cctn.
Institutions Currently Participating in JDRF Canadian Clinical Trial Network

- Ottawa
  - Children’s Hospital of Eastern Ontario
  - Ottawa Hospital Research Institute
  - The Ottawa Hospital Riverside Campus

- Kingston
  - Kingston General Hospital

- Toronto
  - St. Michael’s Hospital
  - The Charles H. Best Diabetes Centre
  - Sunnybrook Hospital
  - Sunnybrook Research Centre
  - The Hospital for Sick Children
  - University Health Network
  - Centre for Global eHealth Innovation

- Waterloo
  - Children’s Hospital of Eastern Ontario
  - Ottawa Hospital Research Institute
  - The Ottawa Hospital Riverside Campus

- Hamilton
  - Lawson Health Research Institute
  - Children’s Hospital, London Health Sciences Centre
  - Western University
  - Robarts Clinical Trials, Clinical Operations Centre
  - St. Joseph Health Care

- London
  - St. Joseph’s Health Care
  - Mount Sinai Hospital
  - Markham-Stouffville Hospital
  - Trillium Health Centre
  - William Osler Brampton Civic Hospital
  - Credit Valley Hospital
Our Partners

The Miller Family – South Alberta Region

“Since our initial contact with JDRF - after Beth was diagnosed - our family has been involved in fundraising and participating in the Walk, Major Gifts Committee, TELUS Walk Committee, Gala, and Third Party events. We have tremendous support from friends, family and the community. We like that JDRF still has a grassroots feel, powered and driven by volunteers who understand because they are somehow affected. We believe – and have to believe – a cure is possible; that keeps us going.”
ADESA Auctions operates a complete vehicle remarketing solution throughout North America and across Canada. Their auction facilities are conveniently located and well-appointed, serving the professional needs of a variety of clients and vehicle segments, including off-lease, off-rental, corporate fleet, repossession, dealer wholesale, heavy equipment and specialty assets. ADESA Auctions also accepts donations of cars, trucks, heavy equipment, tractors, recreational vehicles, boats, ATVs, motorcycles, and snowmobiles. Donations are auctioned and sold to the highest bidder with the net proceeds forwarded to JDRF, in the donor’s name. ADESA Auctions has been a longtime supporter of JDRF through their “Give it Up” donation program, initially piloted in both Winnipeg and Peel Region. With the success of the donation program, ADESA Auctions and JDRF partnered on a national level and continue to see great responses from the community across Canada. Interested donors are asked to please visit giveitup.jdrf.ca/ to find out more about this unique gifting opportunity.

As an organization, Boston Pizza is Canada’s number one casual dining chain and is a Platinum member of Canada’s 50 Best Managed Companies since 1993. The Boston Pizza Foundation has a strong philanthropic presence and through various fundraising initiatives, they have raised over $16 million to support local, national and global non-profit organizations, all of which directly impact the health and well-being of children and families. Since 2001, Boston Pizza Foundation has donated more than $2 million to JDRF through the BP Invitational Golf Tournament, sales of heart-shaped pizzas and paper hearts on Valentine’s Day, and the Boston Pizza Kids Card charity promotion held in the fall in all 350 Boston Pizza restaurants across Canada. The Boston Pizza Foundation made one of the single largest private-sector donations to JDRF Canada for the Artificial Pancreas Project.

*Registered trademark of Boston Pizza Royalties Limited Partnership, used under license

In 2012, Quebecor helped JDRF reach new levels of visibility. The company published JDRF print and web ads and televised a JDRF public service announcement on the TVA network. JDRF sincerely appreciates Quebecor’s support and the efforts of Quebecor’s CFO, Jean-François Pruneau, who was Co-Chair of the JDRF Ride for Diabetes Research in Montreal in 2012 and will continue in this role in 2013. “Quebecor is more than a media conglomerate. First and foremost, we are a company that is proud of its roots and committed to the community,” says Mr. Pruneau. “We are proud to support innovation and help advance diabetes research.” For more information please visit quebecor.com.

Committed to building strong, healthy communities across Canada, TELUS is a long-time supporter of JDRF as the title sponsor of the TELUS Walk to Cure Diabetes in 48 locations across the country. In 2012, more than 4,500 team members, friends and family came together to raise more than $520,000 to help find a cure for type 1 diabetes. This year marks the sixth year of our partnership and, since 2000 TELUS and its team members have contributed more than $6.5 million to JDRF in support of crucial diabetes research. Paul Lepage, Senior Vice-President, TELUS and President of TELUS Health who co-chairs the TELUS Walk to Cure Diabetes with TELUS’ Chief Commercial Officer, Joe Natale, says, “Until a cure is found, TELUS is determined to use the power of our technology and expertise to help deliver better diabetes management. We believe a cure will be found within our lifetime.” For more information please visit jdrf.ca/walk.

Since 2008, Wal-Mart Pharmacy has been a dedicated supporter of JDRF across Canada through corporate gifts, employee participation and providing clinical information on World Diabetes Day. In the last five years, Wal-Mart Pharmacy has raised over $125,000 in support of JDRF and has participated in various events including the JDRF Ride for Diabetes Research and hosted Pharmacists led management of Sick Day Clinics promoting JDRF. In 2012, Wal-Mart Pharmacy generously supported JDRF as the exclusive pharmacy partner for the JDRF Calendar. For more information please visit walmart.ca.
Wayne & Rita Hildahl – Prairie Region

“I don’t ever remember volunteering for JDRF; I just followed Rita’s lead. She got involved with JDRF about six years ago because our son Thomas has T1D. We saw it as an opportunity to engage our whole family in community work, and they keep coming back year after year in some capacity. JDRF is an extremely well run charity, and it is a privilege for us to be involved and raise funds. We have a great time volunteering and planning the Gala; and hope it will make a difference.”
Join the Community!
The TELUS Walk to Cure Diabetes is more than a fundraising event – it is an outdoor celebration where families, friends and organizations raise funds and awareness to make a difference in the lives of over 300,000 Canadians living with type 1 diabetes (T1D). Each year, this inspiring and energetic event continues to attract new participants and community partners.

As JDRF’s largest annual fundraising program, the TELUS Walk brings together more than 45,000 participants who raise funds for research to cure, better treat, and prevent T1D. In 2012, the TELUS Walk to Cure Diabetes was held in more than 70 communities across the country, raising over $7.7 million. This is a testament to the incredible efforts of participants, sponsors, and volunteers. JDRF cannot thank our supporters enough for their endless dedication, compassion, and generosity.

Corporate Sponsor Support
Key to the success of the 2012 program was the overwhelming and continued support of TELUS. More than 4,500 TELUS team members, friends, and family participated in 48 communities, raising more than $520,000 through employee and corporate support for the 2012 TELUS Walk.

As the national title sponsor, TELUS has contributed more than $6.5 million to JDRF through corporate donations and employee fundraising since 2000.

JDRF also recognizes the significant support of our long-time national sponsor LifeScan and national supplier Sun-Rype who have contributed through sponsorship, in-kind donations, fundraising and participation.

Thank you to all our sponsors, volunteers, and participants for continuing to amaze us with their incredible support and fundraising efforts. Their contributions are instrumental in the success of the TELUS Walk to Cure Diabetes. We look forward to another successful year in 2013. For more information please visit jdrf.ca/walk.

“TELUS is committed to supporting healthy communities across Canada. It’s what’s behind our “Give where we Live” philosophy, and a big part of the reason we partner with JDRF for the TELUS Walk,” said Joe Natale, TELUS Chief Commercial Officer. “We’re proud to be part of the committed teams who inspire a nation of walkers to make a difference. Every step we take – as sponsors, team captains, and individual participants – brings us one step closer to getting the funding we need, and finding a cure for diabetes.”
Each year, the JDRF Ride for Diabetes Research continues to increase in popularity. In 2012, more than 23,500 people participated at 22 sites across the country including four new locations: Red Deer, St. John’s, Toronto – Real Estate Challenge and Windsor. This high-energy stationary ride brings together business leaders and employees from across Canada in a friendly competition to see who can show the most team spirit and raise the most funds for type 1 diabetes (T1D) research.

JDRF is thrilled that the 2012 JDRF Ride program raised over $7.5 million. Each year, the growth and success of the JDRF Ride is a direct result of the hard work and enthusiasm of JDRF volunteers and staff.

The 2012 JDRF Ride Program, for the first time, featured two companies – TD Bank & Scotiabank - that surpassed the $1 million level in funds raised. In total, 384 companies put the JDRF Ride on their calendar and engaged employees to participate.

We would like to thank our corporate leaders, participants and volunteers across Canada whose dedicated efforts contributed to the success of the 2012 JDRF Ride campaign. We look forward to your continued support in the 2013 JDRF Ride season. For more information please visit jdrf.ca/ride.

The key ingredients that make the JDRF Ride so successful are the friendly competition among the teams and corporations, that it is a great team building opportunity, and that it is simply a lot of fun. These elements ensure that riders, and companies, return year after year to enjoy the infectious enthusiasm of the JDRF Ride.

My personal favorite memory of the Ride was the pride I had looking over a sea of riders, laughing and responding to the music, and noticing the waves of corporate colors participating. It was unforgettable! - JP Savage, National Chair, JDRF Ride for Diabetes Research
The Gallos Family – Prairie Region

“We became involved with JDRF when we attended an event held at the Playhouse with the Royal Canadian Air Farce. Since then we have attended or participated in the planning of A Starry Starry Night Gala. Ed’s older brother was diagnosed with T1D as a child. Giving back to the community is extremely important to us and always has been for over 40 years. The stories of the Foundation that are highlighted every year at the Gala continue to move us and illustrate why we remain involved.”

Galas

In communities across Canada, thousands of JDRF supporters join forces for an elegant evening to raise funds, connect and celebrate. For many of our volunteers, community partners, donors, sponsors, staff and guests, these Galas are the social event of the year. JDRF Galas represent a core fundraising program for the Foundation. In 2012, more than 3,500 people attended Galas in nine cities* nationwide and raised an impressive $2.9 million.

Chosen with the help of JDRF Chapters and their Gala Committee, all galas across Canada have unique themes for their evening celebrations. Montreal dazzled guests with an elegant gala evening for JDRF, while Mississauga hosted their first annual “Starlight Soiree by the Lake”. Winnipeg celebrated their 25th anniversary of “A Starry Starry Night”, while guests in Calgary realized “The Sky’s the Limit”. Edmonton treated their guests to an evening of “Denim & Diamonds”, and Vancouver guests joined in with “Gatsby Glamour”. Both Victoria and Nanaimo enjoyed “The Dream is Taking Flight” and Kelowna guests were “Making Diabetes History”. Regardless of the theme, each year guests enjoy a delectable formal dinner, entertainment, dancing, silent and live auctions and JDRF’s signature Fund A Cure.

Similar to a live auction, Fund A Cure provides guests with the opportunity to donate the gift level of their choice and receive a Fund A Cure Bear, as well as a tax receipt for their contribution.

We would like to thank the many volunteers and supporters for their generosity, and for making these very special fundraising events possible. For more information please visit jdrf.ca/galas.

*The Toronto Gala is held every two years.
A diagnosis with type 1 diabetes (T1D) can often be confusing and overwhelming. As an organization founded and driven by individuals and families personally affected by T1D, JDRF understands the importance of providing social, emotional, and practical support, and information for all ages and all stages of T1D. Established in 2006, JDRF’s Outreach Program operates nationally through all Chapters and continues to update, evolve, and introduce new initiatives.

**Bag of Hope**
The Bag of Hope has evolved to appeal to a broader audience of individuals newly diagnosed with T1D. Sponsored by Roche (Accu-Chek), the Bag of Hope contains a variety of reference and educational materials. Once an individual receives a Bag of Hope they become part of JDRF’s Family Network. Since the initial release of the program, JDRF has connected with almost 2,500 families, many of whom have become involved with JDRF through our mentoring program, or core fundraising programs as volunteers or participants. To request a Bag of Hope visit jdrf.ca/newlydiagnosed.

**School Advisory Toolkit**
The School Advisory Toolkit, generously supported by LifeScan Canada (OneTouch), provides information to assist parents in educating and communicating with their child’s school. The School Advisory Toolkit became available online in 2012 at jdrf.ca and onetouch.ca; and was also distributed in LifeScan’s Youth Packs at 23 TELUS Walk locations, and through JDRF Chapters. To download the School Advisory Toolkit visit jdrf.ca/schoolkit.

**Adult Toolkits**
JDRF has had many requests for information for adults living with T1D so in 2012, production of two Adult Toolkits began. These toolkits focus on topics for the newly diagnosed adult as well as the adult that has lived with T1D for a number of years. To download the Adult Type 1 Toolkit visit jdrf.ca/adultswitht1d.

**Outreach Volunteer Network**
The Outreach Program is strengthened by our dedicated National Outreach Committee. Across Canada, a group of volunteers, led by Janice Hicks, National Outreach Chair, communicate four times a year providing national updates on programs, sharing best practices, brainstorming new concepts, overcoming challenges, and providing an opportunity to ask questions.

JDRF is committed to developing new and better treatments that improve the lives of people with T1D in the near term, and keep them healthy while we advance toward a cure. In 2012, JDRF held Diabetes Research Symposiums in 18 cities across Canada to hear the latest updates from JDRF-funded researchers and to listen to inspiring motivational stories by Diabetes Champions. JDRF strategically partners with industry, governments, foundations, academia, and clinicians to ensure that JDRF and its partners are aligned and working toward a common goal of curing, treating, and preventing T1D. These symposiums allow current JDRF partnerships and research updates to be presented in intimate settings to audiences across Canada. If you’re looking for the latest updates on JDRF-funded research, look no further. Contact your local chapter to attend the next Diabetes Research Symposium near you.

JDRF is grateful to our national sponsors – Bayer, Eli Lilly, Loblaw and Medtronic – for their generous support.

**Youth Ambassador Chase Pelletier shows off his famous go cart to Janice Hicks, National Outreach Chair at a JDRF Outreach event.**
JDRF’s ‘Kids for a Cure’ are Living Proof that a Cure for T1D is Within Reach.

On November 27, 2012, 40 inspirational Canadian children living with type 1 diabetes (T1D) traveled to Ottawa with their families and met with Members of Parliament and Senators as part of JDRF’s Kids for a Cure Day. Kids for a Cure was an action packed event. Our Living Proof Champions had over 40 meetings with Members of Parliament and Senators where they discussed the challenges they face living with T1D and the importance of expanding JDRF Canadian Clinical Trial Network (JDRF CCTN) across Canada.

Through this event, JDRF was able to identify new champions on Parliament Hill to help increase awareness about T1D and JDRF.

Thank you to our 40 JDRF Living Proof Champions and their families for making this such a successful and inspirational experience.

JDRF would also like to thank Eli Lilly Canada Inc. for their support in our Kids for a Cure event.

Prime Minister Stephen Harper meets with Living Proof Champions from across Canada with T1D for a photo on Parliament Hill as part of JDRF’s Kids for a Cure Day on November 27, 2012.

“Kids for a Cure gave me the opportunity to visit Parliament Hill and meet with Members of Parliament to seek their support to expand JDRF CCTN across the country. As a Manitoban, additional funding for JDRF CCTN means I may have an opportunity to participate in a trial.” Makyla Sever, Living Proof Champion, Winnipeg, Manitoba
Craig & Jacqueline Stuart – BC & Yukon Region

“With Jack’s diagnosis, JDRF became our focus. JDRF wrapped their arms around us and provided support. As a family, we decided we didn’t want to sit on the sidelines. Jack said I think we can make a difference; if we raise more money we can hire more scientists to find a cure. That was our initial motivation and it continues to drive us as a family. Fundraising and participating in the TELUS Walk to Cure Diabetes with our team the Jack of Hearts is our focus. We treat it like a business, and hopefully a cure is imminent.”

National Diabetes Awareness Month and World Diabetes Day

As we all know, anyone living with diabetes understands that this disease never takes a holiday. It is with you 24/7 and requires tight management to ensure a healthy being. So, what is the importance of November being National Diabetes Awareness Month and November 14th being World Diabetes Day? Well, it’s simple: Diabetes Awareness Month is an opportunity to raise awareness in support of over 3 million Canadians who live with diabetes. It is an opportunity to bring together and connect our communities and help shine the spotlight on the seriousness of this disease.

Each November JDRF, along with founding sponsor Novo Nordisk Canada engages constituents, partners, volunteers and advocates across the country to raise their voice and awareness about diabetes. One of our favorite activities during the month of November is the Annual JDRF Youth Video Contest. For the fifth year, JDRF invited youth aged 10 and older to submit a video focused on this year’s theme “My diabetes journey...”. We were thrilled to have Kernels as a corporate partner for the very first time and appreciate their support in prizing and promotions. The top three entries were selected by our Leadership Volunteer Panel and public voting took place on JDRF’s website. The winner of this year’s contest was 20 year old, Emilee Wilson from Conestogo, Ontario for her video “It’s hard to dance with the devil on your back”. Diagnosed with T1D when she was just a year old, Emilee uses this video to show the struggles she went through with eating disorders and how she was able to take control of her diabulimia and get her diabetes management back on track. To learn more about the video contest, please visit our website at jdrf.ca/videocontest.

At the heart of the month, World Diabetes Day (WDD) is celebrated every year on November 14. It engages millions of people worldwide in diabetes advocacy and awareness. World Diabetes Day was created in 1991 by the International Diabetes Federation and the World Health Organization in response to growing concerns about the escalating number of people living with diabetes around the world. World Diabetes Day became an official United Nations Day in 2007 focusing on campaigns that draw attention to issues of paramount importance to the diabetes world and keeping diabetes firmly in the public spotlight. While the themed campaigns last the whole year, the day itself is celebrated on November 14, to mark the birthday of Sir Frederick Banting who, along with Dr. Charles Best, first conceived the idea which led to the discovery of insulin in 1922.

JDRF offices across the country mark this official day by celebrating and engaging their local communities by lighting local monuments in blue, hosting blue events, educational events, securing local proclamations, press conferences, forming human blue circles, political events, races, and promoting activities on social media, just to name a few. We encourage you to join the campaign and help us raise our voice.

JDRF would like to thank our founding sponsor, Novo Nordisk Canada, supporters, diabetes Champions and friends who made World Diabetes Day and Diabetes awareness month such a success.
The Stewart Family – South Central Ontario Region

“When Jackson was diagnosed we became so proactive about finding out everything we could about T1D. As a family, we volunteer, participate in the Walk and raise funds and awareness through Karate Chops Diabetes, and our involvement will continue to grow. We have a great support network but are always looking to get more people involved – more focus, more funds, more funded research. JDRF is an incredible organization, and they continue to motivate us to keep fighting for a cure.”

T1D Doesn’t Know any Borders

While we are all connected to the type 1 diabetes (T1D) community across Canada we are also connected to our friends beyond our borders. JDRF Canada is one of seven international affiliates all working toward a common goal of finding a cure for T1D and its complications through the support of research. Here are just a handful of inspiring events and stories from some of our JDRF friends around the globe.

Australia

In 2012, 115 members of the Australian T1D community took part in the second annual JDRF Jump to Cure Diabetes by skydiving “Down Under.” The event, which took place on various dates in March in the capital cities of all six Australian states, raised more than $176,000 for JDRF.

UK

It was an especially big year for JDRF UK. In June, 2012, Her Royal Highness (HRH) The Duchess of Cornwall, was named the affiliate’s first President. The exciting news followed on the heels of The Duchess’ visit in February 2012 to the Wellcome Trust Clinical Research Facility in Cambridge, where she met with leading T1D researchers to learn more about the disease and the research funded by JDRF.

United States

There was continued success at the New York Chapter of JDRF US with “Row for the Cure”. Teams from two upstate New York high schools put aside their historic rivalry this summer, and joined forces in a unique fundraiser for JDRF. The teams rowed the entire width of New York State along the Erie Canal—a total of 340 miles and raised over $71,000 for JDRF.

Denmark and the Netherlands

Excitement could also be found in 2012 for JDRF Denmark, where many events took place to support T1D research. These events included the JDRF Team Copenhagen Marathon, Skodsborg Marathon in support of JDRF, and the annual Rock the Cure featuring local celebrities.

Israel

In 2012, JDRF Israel had a successful year creating awareness and raising funds in support of T1D research. Their fundraising initiatives included an exciting Gala Evening and the Tel Aviv Marathon, and their awareness programs included their Annual Conference and summer camps.

The Stewart Family – South Central Ontario Region

“When Jackson was diagnosed we became so proactive about finding out everything we could about T1D. As a family, we volunteer, participate in the Walk and raise funds and awareness through Karate Chops Diabetes, and our involvement will continue to grow. We have a great support network but are always looking to get more people involved – more focus, more funds, more funded research. JDRF is an incredible organization, and they continue to motivate us to keep fighting for a cure.”
The Pelletier Family – South Central Ontario Region

“When Chase was diagnosed we were determined to make sure he understood the disease and knew diabetes couldn’t put limitations on what he could achieve as long as he put his management first. He is in control of his own destiny because he is part of the solution. From public speaking to fundraising efforts tied to Chase’s Racing Program and Karate Chops Diabetes, we work hard to raise awareness and funds for diabetes research. We are inspired and powered by individuals like Charlie Kimball. He is one of many, that shows us how far we have come and the advances made in JDRF’s work.”
With the dedication and support of our national partners, JDRF can continue on our mission to cure, better treat and prevent type 1 diabetes (T1D). We are proud to partner with the following organizations and want to thank them for their commitment to JDRF.
The Leach Family – South Alberta Region

“When our first-born daughter, Courtney, was diagnosed at 22 months of age the nurses kept ensuring us they are working on a cure. We questioned who is working on this cure and how can we help – that led us to JDRF. Over the years we have been involved in fundraising for golf tournaments and the Walk; today I am primarily involved with the organizing committee for the Hope Gala, but we participate in as many programs as we can. Initially our motivation was to find a cure for our baby; today it is more about increasing awareness about the disease and why it is so important to find a cure. JDRF is looking at different avenues of research into various cures and treatments. If anyone is going to find a cure it will be an organization as big and global as JDRF.”
BOSA Development Corp.
Calgary Herald
Canaccord Wealth Management
Canada Safeway Ltd.
Claire and Bryan Haynes
CN Employees’ and Pensioners’ Community Fund
Colliers International
Collumbin Family Fund at the Toronto Community Foundation
Corby Distilleries Limited
Cormark Securities Inc.
Cottonwood Shots For Kids
Crew Energy Inc.
CTV Atlantic
CTV Ottawa
DC Bank
Debra and Dr. Sidney Zucker
Dinner with the Chiefs - Peel Regional Police
Edmonton Community Foundation
Eileen Sallis Golf Tournament
Evelyn and David Kozloff
Fifty 50 Foods LP
Gail and Jimmy Garfinkle
GlaxoSmithKline Inc.
Global Edmonton
Global Toronto
GMP Securities
Grant Family Golf Tournament
Heather and Ron Miller and Family
Hyatt Regency Vancouver
Intria
J. Edward Brockhouse
Jewish Community Foundation of Montreal
Juvenile Diabetes Golf Classic
Kristin and Ashit Dattani
Loblaw Group of Companies
Lois and Tim O’Neill
London Drugs Limited
Longo’s
Myron Advertising + Design
Norman Warner
Oliver & Bonacini Restaurants
Pentian Construction
Piller’s
Reader’s Digest
Real Estate Weekly - Edmonton
Regina JDRF Charity Golf C/O Jeff Stepan
Riley Beatty 2nd Annual Skate-a-Thon
Rogers Calgary Radio Group
Royal Oak Audi
Sanofi
Scott Bolton
Shelley and Alan Norris
Sheraton Ottawa Hotel
Silpada Designs Canada
Sobeys Inc. - Edmonton
Spin Master Ltd.
The Abercrombie Foundation
The Bagg Family Fundraisers; Spring Fling; Cuisine for a Cure; Swim for a Cure
The Barrie Advance
The Bridle Bash Foundation
The Georgia Straight
The Mary and Gordon Christopher Foundation
The Woodbridge Company Limited
Toronto Community Foundation
Touch a Truck Moncton
Transamerica Life Canada
UPS
Vinyl 95.3
Walmart Canada Corp.
2 Anonymous
Gift Amount $10,000 - $24,999
A Concert for the Kids
A. Mantella & Sons Limited
A.B.C. Recycling Ltd.
Abbott Laboratories Limited
Alberta and Northwest Territories Regional Council of Carpenters and Allied Workers
All Hockey International Ball Hockey Tournament
Andrew Wilkin
Angela Homer and Prentice Lee
Aon Parizeau Inc.
Arthur J.E. Child Foundation
ATCO
Atlantic Provinces Trucking Association Bain & Company
Bank of America Merrill Lynch
Barbara J. and Robert C. Armstrong
Barbecues Galore
Barrie Rose
Bayshore Capital Inc.
Beatrijs and Bruce Williams
Bill and Sharon LeClair
Bill Gallagher - Avenir Sports Entertainment
Blema and Arnold Steinberg Family Foundation
Bonny & Claude Chapman
Branca & Bruce Pachkowski
Brass Hill Investments Ltd.
Broadridge
C.W.F Charity Hockey Fund
Cabinet Solutions
Cadillac Fairview Corporation Limited Canada Inc.
Canadian’s Research-Based Pharmaceutical Companies
Canadian Jewellers Association
Carmen and Robert Carbone
Caroline and Alistair Corbett
CAW
Children’s Books for Charity
Cindy Innes and the late Drew Innes
Craig-Casgrain Fund of Tides Canada Foundation
CRM Dynamics
Crowne Plaza Moncton
Cushman & Wakefield
CYCLE 4: What Matters Foundation
D & H Ltd.
Dance 4 Diabetes - Hannah Hempinstall
Daniel Fernandes
David Bird
Davies, Ward, Phillips & Vineberg LLP
Debbie and Danny Kornhauser
Demtra Sheet Metal Industries Ltd.
Dentistry Canada Fund
Dennis and Elizabeth O’Rourke
Diabetes Express
DIVCO Foundation
Duca Financial Services
Elaine and Barry Mintz
Eldon & Anne Foote Foundation at Edmonton Community Foundation
Electri-Tech Services Inc.
EnCana Corporation
Ernie and Peggie Stevens
Esdale Printing Company
Gary Bluestein Charitable Foundation
Genworth Financial Canada
Gestion Soplajoey Inc
Global BC
GM Sernas & Associates Ltd.
Employee Charitable Trust Fund
Goodmans LLP
Grayross Foundation
Great-West Life
Gregory Cochrane
Greta and Peter Reiskind
Jennifer Hacking & Family – South Western Ontario Region

“Brittany’s diagnosis and finding a cure was the driving force for us to get involved with JDRF and the TELUS Walk. We have learned so much through JDRF’s amazing support network, sharing of knowledge, and advocacy, and see how the funds raised are being used. We believe in the avenues being taken, and think of JDRF as the root to a cure for diabetes. This is why we continue to participate, raise funds and volunteer.”

Canadian Research Funded in 2012

**Immune Therapies**

**Santamaria, Pere, MD, PhD**
Strategic Research Agreement
Expansion of autoregulatory CD4+ memory with pMHC class II nanoparticles
The University of Calgary, Calgary, AB

**Santamaria, Pere, MD, PhD**
Innovative Grant
Role of a cross-reactive gut microbial peptide in diabetes
The University of Calgary, Calgary, AB

**Santamaria, Pere, MD, PhD**
Scholar Award
A novel vaccine for the prevention and cure of type 1 diabetes
The University of Calgary, Calgary, AB

**Churchill, Thomas, PhD**
Priority Research Grant
Improving Pancreas Preservation for the Isolation, Purification and Transplantation of Human Islets
University of Alberta, Surgical-Medical Res. Inst., Edmonton, AB

**Santamaria, Pere, MD, PhD**
Strategic Research Agreement
Peptide MHC Class-I Coated Gold Nanoparticles for treatment of T1D
University Technologies International Inc., Calgary, AB

**Montane, Joel, PhD**
Postdoctoral Fellowship Award
Prevention of diabetes by T regulatory cell recruitment to the islet
University of British Columbia, Vancouver, BC

**Kieffer, Timothy, PhD**
Strategic Research Agreement
Novel Biomarkers for Diabetes
University of British Columbia, Vancouver, BC

**Tan, Rusung, MD, PhD**
Strategic Research Agreement
IL-17 in type 1 diabetes
University of British Columbia, Vancouver, BC

**Dutz, Jan, F.R.C.P.C.**
Postdoctoral Fellowship Award
Prevention of diabetes by T regulatory cell recruitment to the islet
University of British Columbia, Vancouver, BC

**Dutz, Jan, F.R.C.P.C.**
Mucosal Immunity
Intestinal barrier function and TLR signaling in T1D
University of British Columbia, Vancouver, BC

**Danksa, Jayne, PhD**
Strategic Research Agreement
Mechanisms of Type 1 Diabetes Protection by Manipulation of Gut Microflora
The Hospital for Sick Children, Toronto, ON

**Dixon, George, PhD**
Component of International Government Grant
Establishment of Canadian T1D Clinical Trial Network Coordinating Centre
University of Waterloo, Waterloo, ON

**Delovitch, Terry, PhD**
Innate Immunity Grant
Novel Strategies for Innate Immune Modulation of Type 1 Diabetes (T1D)
Robarts Research Institute, London, ON

**Thebault, Pamela, PhD**
Postdoctoral Fellowship Award
Role of memory T cells in pathogenesis of Type 1 Diabetes
Hôpital Maisonneuve-Rosemont, Centre de Recherche, Montreal, QC

**Polychronakos, Constantin, MD**
Priority Research Grant
Rare but highly penetrant alleles in the genetics of type 1 diabetes
McGill University Health Centre - Montreal Children's Hospital, Montreal, QC

**Ramanathan, Sheela, PhD**
Innovative Grant
Role of IL-15 in the pathogenesis of TID in the NOD mouse
Université de Sherbrooke - Service de la recherche et de la création, Sherbrooke, QC

**Piccirillo, Ciriaco, PhD**
Priority Research Grant
Integrating genetics with markers of immune response.
McGill University Health Centre - Montreal Children's Hospital, Montreal, QC

**Polychronakos, Constantin, MD**
Priority Research Grant
Novel Genetic Susceptibility Loci for Type 1 Diabetes
McGill University Health Centre - Montreal Children's Hospital, Montreal, QC
**Beta Cell Therapies**

**Korbutt, Gregory, PhD**  
Bioengineering  
*Bioengineering a highly vascularized ectopic site for islet transplantation*  
The Governors of the University of Alberta, Edmonton, AB

**MacDonald, Patrick, PhD**  
Career Development Award  
*Metabolic and immunologic interactions in islet graft function and loss*  
The Governors of the University of Alberta, Edmonton, AB

**Shapiro, A.M. James, MD, PhD**  
Center Grant  
*Islet Protection, Regeneration and New Sites for Implantation*  
The Governors of the University of Alberta, Edmonton, AB

**Shapiro, A.M. James, MD, PhD**  
Strategic Research Agreement  
*Caspase Inhibition in Clinical Islet Transplantation*  
University of Alberta - Dept. of Surgery, Edmonton, AB

**Santamaria, Pere, MD, PhD**  
Priority Research Grant  
*Regenerative capacity of the diabetic NOD pancreas upon diabetes reversal*  
The University of Calgary, Calgary, AB

**Korbutt, Gregory, PhD**  
Strategic Research Agreement  
*Encapsulation of Neonatal Porcine Islets for Clinical Transplantation*  
The Governors of the University of Alberta, Edmonton, AB

**Hoffman, Brad, PhD**  
Innovative Grant  
*Cytokine induced changes in the beta-cell epigenome*  
University of British Columbia, Vancouver, BC

**Baradar Jalili, Reza, PhD**  
Postdoctoral Fellowship Award  
*Development and Application of a Composite Non-Rejectable Islet Graft*  
University of British Columbia, Vancouver, BC

**Bischoff, Loraine, MD**  
Postdoctoral Fellowship Award  
*Protection of islet grafts by recruitment of T regulatory cells*  
University of British Columbia, Vancouver, BC

**Kieffer, Timothy, PhD**  
Priority Research Grant  
*Targeted Expression of Insulin to Intestinal Endocrine Cells*  
University of British Columbia, Vancouver, BC

**Verchere, C. Bruce, PhD**  
Priority Research Grant  
*CCL22-Mediated Protection of Islet Transplants*  
University of British Columbia, Vancouver, BC

**Lim, Gareth, BSc**  
Postdoctoral Fellowship Award  
*Role of the 14-3-3 proteins in type 1 diabetes*  
University of British Columbia, Vancouver, BC

**Johnson, James, PhD**  
Priority Research Grant  
*Targeting the Raf1 signaling node for beta-cell survival and function*  
University of British Columbia, Vancouver, BC

**Johnson, James, PhD**  
Strategic Research Agreement  
*High-throughput analysis of beta-cell-preserving paracrine factors*  
University of British Columbia, Vancouver, BC

**Lynn, Francis, PhD**  
Career Development Award  
*The role of Sox4 in beta cell genesis and proliferation*  
University of British Columbia, Vancouver, BC

**Bruin, Jennifer, PhD**  
Postdoctoral Fellowship Award  
*Generation of Mature Beta Cells from Human Embryonic Stem Cells*  
University of British Columbia, Vancouver, BC
Dr. Sheldon & Norma Finkelstein and Family – Toronto Region

“I initially became involved with JDRF in 2001 as a member of the Lay Review Committee. Our son has T1D. Presently I am a member of both JDRF’s Canadian Clinical Trial Network (JDRF CCTN) and JDRF Canada’s Board of Directors. I also Chair the Great Escape Golf event. My fundraising activities are in support of the Gala and the Great Escape Golf event, which has raised more than $2 million over ten years. My current motivation is being directly involved in moving research forward to prevent complications and cure diabetes. What has impressed me about JDRF Canada is how quickly and successfully they created a Canadian Clinical Trial Network for diabetes research.”
Glucose Control

Carlen, Peter, MD, FRCP(C)
Priority Research Grant
Juvenile Hypoglycemic Seizures: Consequences, Mechanisms and Treatment
University Health Network, Toronto, ON

Asztalos, Elizabeth
Strategic Research Agreement
CONCEPTT - International Studies
The Centre for Mother, Infant, and Child Research (CMiCR), Toronto, ON

Rabasa-Lhoret, Remi, PhD, MD
Innovative Grant
Closed-loop control of glucose levels after meal intake in type 1 diabetes
Institut de Recherches Cliniques de Montreal, Montreal, QC

Complications Therapies

Pacaud, Danièle, MD
Strategic Research Agreement
Corneal Confocal Microscopy to detect Diabetic Neuropathy in Children
The University of Calgary, Calgary, AB

Zochodne, Douglas, MD
Interconnecting and Synergistic Pathways
Diabetic Neuropathy, Neuronal Insulin And Its Interaction With Age-Rage
The University of Calgary, Calgary, AB

Fernyhough, Paul, PhD
Priority Research Grant
Metabolic regulation of neuronal mitochondrial function in diabetes
St. Boniface General Hospital, Winnipeg, MB

Fernyhough, Paul, PhD
Strategic Research Agreement
Muscarinic receptor antagonists for treatment of diabetic neuropathy
St. Boniface General Hospital, Winnipeg, MB

Touyz, Rhian, MD, PhD
Center Grant
TOUYZ: NOX-derived ROS: Renal and Vascular Complications of Type 1 Diabetes
Ottawa Hospital Research Institute, Ottawa, ON

McBride, Heidi, PhD
Strategic Research Agreement
Investigations into the rise and fall of ROS in the hyperglycaemic state
Ottawa Heart Institute Research Corporation, Ottawa, ON

Paterson, Andrew, MB, ChB
Strategic Research Agreement
Genetics of the decline in Glomerular Filtration Rate in Type 1 Diabetes
The Hospital for Sick Children, Toronto, ON

Perkins, Bruce, MD
Strategic Research Agreement
Creation of the “Canadian 50-Year Medalist Cohort”
University Health Network, Toronto, ON

Perkins, Bruce, MD
Strategic Research Agreement
Corneal Nerve Fiber Density as a Biomarker of Early Neuropathy
University Health Network, Toronto, ON

Rodin, Gary M., MD
Priority Research Grant
Longitudinal Study of Eating Disturbances, Psychosocial Functioning, and Medical Complications in Adolescent Girls and Young Women with Type 1 Diabetes Mellitus
University Health Network, Toronto General Hospital, Toronto, ON

Rodin, Gary M., MD
Priority Research Grant
Eating and psychosocial functioning: A controlled study of pre-adolescent girls with insulin-dependent diabetes mellitus
Toronto Hospital, Toronto, ON

Geraldès, Pedro, PhD
Advanced Postdoctoral Fellowship
Role of SHP-1 regulating PDGF and EGF actions in diabetic complications
Université de Sherbrooke, Sherbrooke, QC

Geraldès, Pedro, PhD
High Priority, Short Term Award
Insulin actions in podocyte injury associated to diabetic nephropathy
Université de Sherbrooke - Service de la recherche et de la création, Sherbrooke, QC

AKUDE, Eli, PhD
Postdoctoral Fellowship Award
Understanding the molecular mechanisms that produce diabetic dysautonomia
McGill University, Montreal, QC

Cooper, Ellis, PhD
Priority Research Grant
Hyperglycemia-induce ROS impairs synaptic transmission in autonomic ganglia
McGill University, Montreal, QC

Partnerships

Canada V
Partnership Program
Canadian Institutes of Health Research, Ottawa, ON

JDRF Canadian Clinical Trial Network
International Government Grant/Transportfolio
JDRF Canadian Clinical Trial Network Coordinating Center (CCTN)
Financial Review 2012

Consolidated Balance Sheet as at December 31, 2012

<table>
<thead>
<tr>
<th></th>
<th>2012 ($)</th>
<th>2011 ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Current Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>6,026,524</td>
<td>11,496,280</td>
</tr>
<tr>
<td>Short-term investments</td>
<td>1,674,094</td>
<td>1,486,235</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>1,229,853</td>
<td>954,283</td>
</tr>
<tr>
<td>Grant receivable</td>
<td>2,211,504</td>
<td>418,415</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>96,421</td>
<td>94,704</td>
</tr>
<tr>
<td><strong>Capital Assets</strong></td>
<td>250,405</td>
<td>288,030</td>
</tr>
<tr>
<td><strong>Intangible Assets</strong></td>
<td>43,377</td>
<td>61,967</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>11,238,396</td>
<td>14,449,917</td>
</tr>
</tbody>
</table>

|                    |                |                |
| **Liabilities**    |                |                |
| **Current Liabilities** |          |                |
| Accounts payable, accrued and deferred support | 756,831  | 996,170       |
| Deferred leasehold | 284,527        | 210,026        |
| **Total Current Liabilities** | 1,041,358 | 1,206,196     |

|                    |                |                |
| **Net Assets**     |                |                |
| Unrestricted       | 10,405,320     | 13,508,218     |
| Restricted for endowment purposes | 85,500      | 85,500         |
| **Total Net Assets** | 10,490,820 | 13,593,718    |

<table>
<thead>
<tr>
<th>Functional Expenses</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCTN</td>
<td>41%</td>
</tr>
<tr>
<td>Management and General</td>
<td>5.7%</td>
</tr>
<tr>
<td>Research, Education, and Advocacy</td>
<td>45%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>8.2%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Revenues</strong></th>
<th>2012 ($)</th>
<th>2011 ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public Support Revenues</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Campaigns</td>
<td>23,823,149</td>
<td>24,918,138</td>
</tr>
<tr>
<td>Direct response</td>
<td>115,641</td>
<td>104,003</td>
</tr>
<tr>
<td>JDRF CCTN grant revenue</td>
<td>6,355,477</td>
<td>15,806,203</td>
</tr>
<tr>
<td><strong>Total Public Support Revenues</strong></td>
<td>30,294,267</td>
<td>40,828,344</td>
</tr>
<tr>
<td><strong>Other Revenues</strong></td>
<td>111,227</td>
<td>171,162</td>
</tr>
<tr>
<td>Investment income</td>
<td>30,405,494</td>
<td>40,999,506</td>
</tr>
<tr>
<td><strong>Total Other Revenues</strong></td>
<td>30,516,721</td>
<td>41,170,666</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td>30,811,028</td>
<td>42,008,010</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Expenses</strong></th>
<th>2012 ($)</th>
<th>2011 ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct Expenses</strong></td>
<td>4,724,954</td>
<td>5,042,349</td>
</tr>
<tr>
<td><strong>Other Expenses</strong></td>
<td>25,680,540</td>
<td>35,957,157</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Surplus (deficit) of the year</strong></th>
<th>2012 ($)</th>
<th>2011 ($)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unrestricted</strong></td>
<td>(3,102,898)</td>
<td>5,883,365</td>
</tr>
<tr>
<td><strong>Restricted for endowment purposes</strong></td>
<td>85,500</td>
<td>85,500</td>
</tr>
<tr>
<td><strong>Total Surplus (deficit) of the year</strong></td>
<td>28,783,438</td>
<td>30,073,792</td>
</tr>
</tbody>
</table>

Report of Management

Management is responsible for the preparation of JDRF’s financial statements and other financial information in this report. This responsibility includes maintaining the integrity and objectivity of the financial records. JDRF maintains a system of internal controls designed to provide assurance that its records include the transactions of its operations.

The financial statements have been reported on by JDRF’s auditors, PricewaterhouseCoopers LLP, Chartered Accountants. The Board of Directors, through its Finance Committee, is responsible for determining that management fulfills its responsibilities in the preparation of the financial statements, and ensures the financial and operational controls of JDRF are adequate.

The Audit Committee reviews the financial statements and meets with the auditors. The auditors have full and free access to management, the Finance Committee, and the Audit Committee in carrying out their work.

The data on this page has been extracted and summarized from the audited financial statements. A complete set of financial statements is available on our website at jdrf.ca or upon request at 1.877.287.3533. Charitable business number: 11897 6604 RR0001.
“When Evan was diagnosed the hospital referred us to JDRF. The first program we got involved with was the mentoring program. I (Kim) wanted to pass on my knowledge and empathy to newly diagnosed families because I came from a situation where I didn’t have a mentor. Although we moved from Toronto to Hong Kong in 2010, we still remain in contact with JDRF, other parents, and continue to give JDRF an annual financial donation. Here in Hong Kong, I am working with a Juvenile Diabetes Association. I am on the Board of Directors and the fundraising committee, and am establishing a mentor program with them. Evan and his three siblings have also started to get involved by raising awareness and money for diabetes.”